Lexeo Therapeutics (LXEO)

• Market cap: $378M
• 1 day: 5.71%
• 5 days: 15.9%
• 1 month: 0.42%
• 3 months: -17.35%
• 6 months: -33.19%
• Year to date: -49.95%
• 1 year: 8.09%
• 5 years: -52.14%
• 10 years: -52.14%
• Sector: Healthcare
• Industry: Biotechnology

About: Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Employees: 59